NextCure Appoints Dr. Lisa M. Coussens to Scientific Advisory Board
BELTSVILLE, Md., Oct. 27, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and...
Cancer
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
MENLO PARK, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third...
Oncocyte to Announce Third Quarter 2022 Financial Results
IRVINE, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve...
Agios and Sagard Healthcare Partners Announce $131.8 Million Purchase Agreement for TIBSOVO® Royalty
Sagard Healthcare Partners Acquires Rights to Agios’ 5% Royalty on TIBSOVO® U.S. Net SalesCAMBRIDGE, Mass. and TORONTO, Oct. 27, 2022...
MDxHealth Reports Q3-2022 Results
NEWS RELEASE - REGULATED INFORMATION27 OCTOBER 2022, 4:00PM EDT / 22:00 CET MDxHealth Reports Q3-2022 Results IRVINE, CA, and HERSTAL,...
Biora Therapeutics Announces Sale of Cell-Free DNA Patent Rights
SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic...
Scip & Savor for a Cure Fundraiser Benefits the International Myeloma Foundation (IMF) and Family Reach
STUDIO CITY, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) today announced the details of the...
iCAD to Report Third Quarter 2022 Financial Results on November 10, 2022
NASHUA, N.H., Oct. 27, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer...
Salarius Pharmaceuticals Presents Favorable Preclinical Data on SP-3164 at the 5th Annual Targeted Protein Degradation Conference
Data showcased novel compound with potential for improved anti-cancer activity over other molecular glues Salarius plans to release additional preclinical...
Rain Therapeutics to Report Third Quarter 2022 Financial Results and Highlights of Recent Progress on November 10, 2022
NEWARK, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage biotechnology company developing precision...
Monopar Announces Timeline of Upcoming Data Events for Validive, Camsirubicin, and MNPR-202
WILMETTE, Ill., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary...
Mustang Bio Announces Phase 1/2 Clinical Trial Data of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy, to be Presented at 11th International Workshop for Waldenstrom’s Macroglobulinemia
MB-106 demonstrated 100% overall response rate in Waldenstrom macroglobulinemia Data to be presented by Fred Hutch’s Dr. Mazyar Shadman WORCESTER,...
UCSF QBI Congratulates Nevan Krogan, Ph.D., as a Recipient of Prestigious French Legion of Honor Award and Welcomes New, Comprehensive Relationship with Institut Pasteur
– Two Academic Powerhouses form Institut Pasteur-UCSF QBI Center of Excellence in Emerging Diseases with Planned Operations/Locations in San Francisco...
Jounce Therapeutics to Announce Third Quarter 2022 Financial Results and Host Conference Call on Thursday, November 10, 2022
CAMBRIDGE, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery...
Sensus Healthcare to Host Third Quarter 2022 Financial Results and Business Update Conference Call on November 3, 2022
BOCA RATON, Fla., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in...
Biomea Fusion Announces First Patient Dosed with Chronic Lymphocytic Leukemia (CLL) in COVALENT-101 Trial
COVALENT-101 now includes patients with relapsed/refractory (R/R) CLLBMF-219 is the first menin inhibitor in the clinic for CLLPreclinical data presented...
PDS Biotech Provides Highlights from Head and Neck Cancer KOL Roundtable
Jared Weiss, MD, Lead Investigator for the VERSATILE-002 clinical trial combining PDS0101 and KEYTRUDA®, presents interim data from the study...
Burning Rock Announces Publication of Prospectus in connection with Direct Listing on the London Stock Exchange
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM AUSTRALIA, CANADA,...
HUTCHMED Initiates a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Oct. 27, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM;...
Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2022 Earnings and Company Updates
CAMBRIDGE, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on...